Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis

World Journal of Gastroenterology

Volumn 20, Issue 10, 2014, Pages 2555-2563

  Bolognesi, Massimo ^a   Di Pascoli, Marco ^a   Verardo, Alberto ^a   Gatta, Angelo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Autonomic dysfunction; Cirrhosis; Hyperdynamic circulatory syndrome; Nitric oxide; Portal hypertension; Splanchnic flow; Splenic circulation

Indexed keywords

ADRENOMEDULLIN; ALBUMIN; ALPHA CALCITONIN GENE RELATED PEPTIDE; CANNABINOID; CARBON MONOXIDE; FUROSEMIDE; MIDODRINE; NITRIC OXIDE; SOMATOSTATIN; SPIRONOLACTONE; TERLIPRESSIN; VASCULOTROPIN; AUTACOID; VASOCONSTRICTOR AGENT;

ARTICLE; ASCITES; AUTONOMIC DYSFUNCTION; COLLATERAL CIRCULATION; HEART OUTPUT; HUMAN; HYPERDYNAMIC CIRCULATORY SYNDROME; ISCHEMIA; LIVER CIRRHOSIS; PORTAL VEIN BLOOD PRESSURE; SPLANCHNIC BLOOD FLOW; SPLEEN BLOOD FLOW; VASODILATATION; ANIMAL; ARTERIAL PRESSURE; BLOOD FLOW; COMPLICATION; DRUG EFFECTS; HEART RATE; HYPERTENSION, PORTAL; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SYNDROME; VASCULAR RESISTANCE;

ANIMALS; ARTERIAL PRESSURE; CARDIAC OUTPUT; COLLATERAL CIRCULATION; HEART RATE; HUMANS; HYPERTENSION, PORTAL; INFLAMMATION MEDIATORS; LIVER CIRRHOSIS; PORTAL PRESSURE; REGIONAL BLOOD FLOW; SIGNAL TRANSDUCTION; SPLANCHNIC CIRCULATION; SYNDROME; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 84896804456     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i10.2555     Document Type: Article

References (115)

1. Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol 2006; 44: 111-117 [PMID: 16274836 DOI: 10.1016/j.jhep.2005.07.036]
2. Carrión JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12: 1791-1798 [PMID: 16823833 DOI: 10.1002/lt.20857]
3. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998; 28: 926-931 [PMID: 9755227 DOI: 10.1002/ hep.510280405]
4. Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985; 1: 325-337 [PMID: 4056346 DOI: 10.1016/S0168-8278(85)80770-4]
5. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 334-339 [PMID: 9918907 DOI: 10.1002/hep.510290203]
6. Jiménez W, Rodés J. Impaired responsiveness to endogenous vasoconstrictors and endothelium-derived vasoactive factors in cirrhosis. Gastroenterology 1994; 107: 1201-1203 [PMID: 7926472]
7. Graupera M, García-Pagán JC, Abraldes JG, Peralta C, Bragulat M, Corominola H, Bosch J, Rodés J. Cyclooxygenasederived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 2003; 37: 172-181 [PMID: 12500202 DOI: 10.1053/jhep.2003.50004]
8. Matei V, Rodríguez-Vilarrupla A, Deulofeu R, Colomer D, Fernández M, Bosch J, Garcia-Pagán JC. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology 2006; 44: 44-52 [PMID: 16799985 DOI: 10.1002/hep.21228]
9. Shah V, Haddad FG, Garcia-Cardena G, Frangos JA, Mennone A, Groszmann RJ, Sessa WC. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest 1997; 100: 2923-2930 [PMID: 9389760 DOI: 10.1172/JCI119842]
10. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998; 114: 344-351 [PMID: 9453496 DOI: 10.1016/S0016-5085(98)70487-1]
11. Sarela AI, Mihaimeed FM, Batten JJ, Davidson BR, Mathie RT. Hepatic and splanchnic nitric oxide activity in patients with cirrhosis. Gut 1999; 44: 749-753 [PMID: 10205218 DOI: 10.1136/gut.44.5.749]
12. Gracia-Sancho J, Laviña B, Rodríguez-Vilarrupla A, García-Calderó H, Bosch J, García-Pagán JC. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J Hepatol 2007; 47: 220-227 [PMID: 17459512 DOI: 10.1016/ j.jhep.2007.03.014]
13. Gaiani S, Bolondi L, Li Bassi S, Santi V, Zironi G, Barbara L. Effect of meal on portal hemodynamics in healthy humans and in patients with chronic liver disease. Hepatology 1989; 9: 815-819 [PMID: 2653993 DOI: 10.1002/hep.1840090604]
14. Bradley SE, Ingelfinger FJ, Bradley GP. Hepatic circulation in cirrhosis of the liver. Circulation 1952; 5: 419-429 [PMID: 14905582 DOI: 10.1161/01.CIR.5.3.419]
15. Moreno AH, Burchell AR, Rousselot LM, Panke WF, Slafsky F, Burke JH. Portal blood flow in cirrhosis of the liver. J Clin Invest 1967; 46: 436-445 [PMID: 6023778 DOI: 10.1172/ JCI105545]
16. Tisdale WA, Klatskin G, Glenn WW. Portal hypertension and bleeding esophageal varices; their occurrence in the absence of both intrahepatic and extrahepatic obstruction of the portal vein. N Engl J Med 1959; 261: 209-218 [PMID: 13674507 DOI: 10.1056/NEJM195907302610501]
17. Gitlin N, Grahame GR, Kreel L, Williams HS, Sherlock S. Splenic blood flow and resistance in patients with cirrhosis before and after portacaval anastomoses. Gastroenterology 1970; 59: 208-213 [PMID: 5448195]
18. Witte CL, Witte MH, Bair G, Mobley WP, Morton D. Experimental study of hyperdynamic vs. stagnant mesenteric blood flow in portal hypertension. Ann Surg 1974; 179: 304-310 [PMID: 4813477 DOI: 10.1097/00000658-197403000-00010]
19. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244: G52-G57 [PMID: 6849394]
20. Lautt WW, Legare DJ. Passive autoregulation of portal venous pressure: distensible hepatic resistance. Am J Physiol 1992; 263: G702-G708 [PMID: 1443145]
21. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986; 6: 287-298 [PMID: 3544222 DOI: 10.1055/s-2008-1040611]
22. Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodés J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 2005; 43: 98-103 [PMID: 15893841 DOI: 10.1016/ j.jhep.2005.02.22]
23. Geerts AM, De Vriese AS, Vanheule E, Van Vlierberghe H, Mortier S, Cheung KJ, Demetter P, Lameire N, De Vos M, Colle I. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. Liver Int 2006; 26: 889-898 [PMID: 16911473 DOI: 10.1111/j.1478-3231.2006.01308.x]
24. Gatta A, Bolognesi M, Merkel C. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis. Mol Aspects Med 2008; 29: 119-129 [PMID: 18036654 DOI: 10.1016/j.mam.2007.09.006]
25. Sherwin R, Joshi P, Hendler R, Felig P, Conn HO. Hyperglucagonemia in Laennec's cirrhosis. The role of portal-systemic shunting. N Engl J Med 1974; 290: 239-242 [PMID: 4808927 DOI: 10.1056/NEJM197401312900502]
26. Benoit JN, Womack WA, Hernandez L, Granger DN. "Forward" and "backward" flow mechanisms of portal hypertension. Relative contributions in the rat model of portal vein stenosis. Gastroenterology 1985; 89: 1092-1096 [PMID: 4043666]
27. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776-778 [PMID: 1706450]
28. Bosch J, Pizcueta P, Feu F, Fernández M, García-Pagán JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am 1992; 21: 1-14 [PMID: 1568769]
29. Sogni P, Moreau R, Gadano A, Lebrec D. The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J Hepatol 1995; 23: 218-224 [PMID: 7499796 DOI: 10.1016/0168-8278(95)80339-4]
30. Hori N, Okanoue T, Sawa Y, Kashima K. Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats. J Hepatol 1997; 26: 1111-1119 [PMID: 9186842 DOI: 10.1016/S0168-8278(97)80120-1]
31. Fernández-Rodriguez CM, Prada IR, Prieto J, Montuenga LM, Elssasser T, Quiroga J, Moreiras M, Andrade A, Cuttitta F. Circulating adrenomedullin in cirrhosis: relationship to hyperdynamic circulation. J Hepatol 1998; 29: 250-256 [PMID: 9722206 DOI: 10.1016/S0168-8278(98)80010-X]
32. Guevara M, Ginès P, Jiménez W, Sort P, Fernández-Esparrach G, Escorsell A, Bataller R, Bosch J, Arroyo V, Rivera F, Rodés J. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998; 114: 336-343 [PMID: 9453495 DOI: 10.1016/S0016-5085(98)70486-X]
33. Pérez-Ruiz M, Ros J, Morales-Ruiz M, Navasa M, Colmenero J, Ruiz-del-Arbol L, Cejudo P, Clária J, Rivera F, Arroyo V, Rodés J, Jiménez W. Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide. Hepatology 1999; 29: 1057-1063 [PMID: 10094946 DOI: 10.1002/hep.510290416]
34. Sacerdoti D, Abraham NG, Oyekan AO, Yang L, Gatta A, McGiff JC. Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats. J Pharmacol Exp Ther 2004; 308: 636-643 [PMID: 14600247 DOI: 10.1124/ jpet.103.057315]
35. Bolognesi M, Sacerdoti D, Di Pascoli M, Angeli P, Quarta S, Sticca A, Pontisso P, Merkel C, Gatta A. Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites. Gut 2005; 54: 1630-1636 [PMID: 16227362 DOI: 10.1136/gut.2004.063735]
36. Atucha NM, Shah V, García-Cardeña G, Sessa WE, Groszmann RJ. Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis. Gastroenterology 1996; 111: 1627-1632 [PMID: 8942743 DOI: 10.1016/S0016-5085(96)70026-4]
37. Whittle BJ, Moncada S. Nitric oxide: the elusive mediator of the hyperdynamic circulation of cirrhosis? Hepatology 1992; 16: 1089-1092 [PMID: 1398490]
38. Battista S, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G. Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 1997; 26: 75-80 [PMID: 9148026 DOI: 10.1016/ S0168-8278(97)80012-8]
39. Cahill PA, Redmond EM, Hodges R, Zhang S, Sitzmann JV. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol 1996; 25: 370-378 [PMID: 8895017 DOI: 10.1016/ S0168/8278(96)80124-3]
40. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-605 [PMID: 10376603 DOI: 10.1038/21224]
41. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 1223-1233 [PMID: 10545521 DOI: 10.1172/JCI7458]
42. Morales-Ruiz M, Jiménez W, Pérez-Sala D, Ros J, Leivas A, Lamas S, Rivera F, Arroyo V. Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Hepatology 1996; 24: 1481-1486 [PMID: 8938184 DOI: 10.1002/ hep.510240630]
43. Angeli P, Fernández-Varo G, Dalla Libera V, Fasolato S, Galioto A, Arroyo V, Sticca A, Guarda S, Gatta A, Jiménez W. The role of nitric oxide in the pathogenesis of systemic and splanchnic vasodilation in cirrhotic rats before and after the onset of ascites. Liver Int 2005; 25: 429-437 [PMID: 15780069 DOI: 10.1111/j.1478-3231.2005.01092.x]
44. Sumanovski LT, Battegay E, Stumm M, van der Kooij M, Sieber CC. Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Hepatology 1999; 29: 1044-1049 [PMID: 10094944 DOI: 10.1002/hep.510290436]
45. Sieber CC, Sumanovski LT, Stumm M, van der Kooij M, Battegay E. In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J Hepatol 2001; 34: 644-650 [PMID: 11434609 DOI: 10.1016/S0168-8278(00)00064-7]
46. Hamilton G, Phing RC, Hutton RA, Dandona P, Hobbs KE. The relationship between prostacyclin activity and pressure in the portal vein. Hepatology 1982; 2: 236-242 [PMID: 7040200 DOI: 10.1002/hep.1840020208]
47. Hou MC, Cahill PA, Zhang S, Wang YN, Hendrickson RJ, Redmond EM, Sitzmann JV. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology 1998; 27: 20-27 [PMID: 9425912 DOI: 10.1002/ hep.510270105]
48. Fernández M, García-Pagán JC, Casadevall M, Mourelle MI, Piqué JM, Bosch J, Rodés J. Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesis. Gastroenterology 1996; 110: 1529-1535 [PMID: 8613060 DOI: 10.1053/gast.1996.v110.pm8613060]
49. Bruix J, Bosch J, Kravetz D, Mastai R, Rodés J. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985; 88: 430-435 [PMID: 3965332]
50. Barriere E, Tazi KA, Rona JP, Pessione F, Heller J, Lebrec D, Moreau R. Evidence for an endothelium-derived hyperpolarizing factor in the superior mesenteric artery from rats with cirrhosis. Hepatology 2000; 32: 935-941 [PMID: 11050042 DOI: 10.1053/jhep.2000.19290]
51. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43: S121-S131 [PMID: 16447289 DOI: 10.1002/ hep.20993]
52. Bolognesi M, Zampieri F, Di Pascoli M, Verardo A, Turato C, Calabrese F, Lunardi F, Pontisso P, Angeli P, Merkel C, Gatta A, Sacerdoti D. Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats. Liver Int 2011; 31: 881-890 [PMID: 21645220 DOI: 10.1111/ j.1478-3231.2011.02509.x]
53. Clemens MG. Does altered regulation of ecNOS in sinusoidal endothelial cells determine increased intrahepatic resistance leading to portal hypertension? Hepatology 1998; 27: 1745-1747 [PMID: 9620353]
54. Chen YC, Ginès P, Yang J, Summer SN, Falk S, Russell NS, Schrier RW. Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats. Hepatology 2004; 39: 1075-1087 [PMID: 15057912 DOI: 10.1002/hep.20151]
55. Fernandez M, Lambrecht RW, Bonkovsky HL. Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: role in modulating mesenteric vascular reactivity. J Hepatol 2001; 34: 812-817 [PMID: 11451163 DOI: 10.1016/S0168-8278(01)00010-1]
56. Bolognesi M, Sacerdoti D, Piva A, Di Pascoli M, Zampieri F, Quarta S, Motterlini R, Angeli P, Merkel C, Gatta A. Carbon monoxide-mediated activation of large-conductance calcium-activated potassium channels contributes to mesenteric vasodilatation in cirrhotic rats. J Pharmacol Exp Ther 2007; 321: 187-194 [PMID: 17229879 DOI: 10.1124/jpet.106.116665]
57. Bátkai S, Járai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis A, Urbaschek R, Garcia N, Sanyal AJ, Kunos G. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-832 [PMID: 11433348 DOI: 10.1038/89953]
58. Domenicali M, Ros J, Fernández-Varo G, Cejudo-Martín P, Crespo M, Morales-Ruiz M, Briones AM, Campistol JM, Arroyo V, Vila E, Rodés J, Jiménez W. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut 2005; 54: 522-527 [PMID: 15753538 DOI: 10.1136/gut.2004.051599]
59. Moezi L, Gaskari SA, Liu H, Baik SK, Dehpour AR, Lee SS. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. Br J Pharmacol 2006; 149: 898-908 [PMID: 17043671 DOI: 10.1038/sj.bjp.0706928]
60. Ros J, Clària J, To-Figueras J, Planagumà A, Cejudo-Martín P, Fernández-Varo G, Martín-Ruiz R, Arroyo V, Rivera F, Rodés J, Jiménez W. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002; 122: 85-93 [PMID: 11781284 DOI: 10.1053/gast.2002.30305]
61. Heller J, Schepke M, Gehnen N, Molderings GJ, Müller A, Erhard J, Spengler U, Sauerbruch T. Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroenterology 1999; 116: 387-393 [PMID: 9922320]
62. Barter F, Tanner AR. Autonomic neuropathy in an alcoholic population. Postgrad Med J 1987; 63: 1033-1036 [PMID: 3451229]
63. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 2008; 57: 1300-1314 [PMID: 18445644 DOI: 10.1136/ gut.2007.144584]
64. Merkel C, Gatta A, Arnaboldi L, Zuin R. Splenic haemodynamics and portal hypertension in patients with liver cirrhosis and spleen enlargement. Clin Physiol 1985; 5: 531-539 [PMID: 4092413 DOI: 10.1111/j.1475-097X.1985.tb00766.x]
65. Gusberg RJ, Peterec SM, Sumpio BE, Meier GH. Splenomegaly and variceal bleeding--hemodynamic basis and treatment implications. Hepatogastroenterology 1994; 41: 573-577 [PMID: 7721248]
66. Takagi K, Ashida H, Utsunomiya J. The effect of splenomegaly on splanchnic hemodynamics in nonalcoholic cirrhosis after distal splenorenal shunt and splenopancreatic disconnection. Hepatology 1994; 20: 342-348 [PMID: 8045494 DOI: 10.1002/hep.1840200212]
67. Okuda K, Kono K, Ohnishi K, Kimura K, Omata M, Koen H, Nakajima Y, Musha H, Hirashima T, Takashi M. Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly. Gastroenterology 1984; 86: 600-610 [PMID: 6698361]
68. Murata K, Shiraki K, Takase K, Nakano T, Tameda Y. Long term follow-up for patients with liver cirrhosis after partial splenic embolization. Hepatogastroenterology 1996; 43: 1212-1217 [PMID: 8908553]
69. Brandt CT, Rothbarth LJ, Kumpe D, Karrer FM, Lilly JR. Splenic embolization in children: long-term efficacy. J Pediatr Surg 1989; 24: 642-644; discussion 644-645 [PMID: 2787859 DOI: 10.1016/S0022-3468(89)80710-9]
70. Kenawi MM, el-Ghamrawi KA, Mohammad AA, Kenawi A, el-Sadek AZ. Splenic irradiation for the treatment of hypersplenism from congestive splenomegaly. Br J Surg 1997; 84: 860-861 [PMID: 9189110 DOI: 10.1002/bjs.1800840637]
71. Williams R, Condon RE, Williams HS, Blendis LM, Kreel L. Splenic blood flow in cirrhosis and portal hypertension. Clin Sci 1968; 34: 441-452 [PMID: 5666874]
72. Alwmark A, Bengmark S, Gullstrand P, Joelsson B, Lunderquist A, Owman T. Evaluation of splenic embolization in patients with portal hypertension and hypersplenism. Ann Surg 1982; 196: 518-524 [PMID: 7125739 DOI: 10.1097/000006 58-198211000-00003]
73. Bolognesi M, Merkel C, Sacerdoti D, Nava V, Gatta A. Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis 2002; 34: 144-150 [PMID: 11926560 DOI: 10.1016/S1590-8658(02)80246-8]
74. Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther 2001; 89: 221-231 [PMID: 11516477 DOI: 10.1016/S0163-7258(01)00124-3]
75. Garcia-Tsao G. Portal hypertension. Curr Opin Gastroenterol 2003; 19: 250-258 [PMID: 15703565]
76. Niederberger M, Martin PY, Ginès P, Morris K, Tsai P, Xu DL, McMurtry I, Schrier RW. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995; 109: 1624-1630 [PMID: 7557147 DOI: 10.1016/0016-5085(95)90652-5]
77. Moleda L, Trebicka J, Dietrich P, Gäbele E, Hellerbrand C, Straub RH, Sauerbruch T, Schoelmerich J, Wiest R. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction. Gut 2011; 60: 1122-1132 [PMID: 21317421 DOI: 10.1136/gut.2010.226407]
78. Newby DE, Hayes PC. Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but 'splanchnic steal'. QJM 2002; 95: 827-830 [PMID: 12454326 DOI: 10.1093/ qjmed/95.12.827]
79. Epstein M, Berk DP, Hollenberg NK, Adams DF, Chalmers TC, Abrams HL, Merrill JP. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 1970; 49: 175-185 [PMID: 5452940 DOI: 10.1016/ S0002-9343(70)80073-0]
80. Merkel C, Gatta A, Milani L, Amodio P, Zuin R. Intrarenal blood flow, circulation time, and cortical vascular volume in patients with cirrhosis. Scand J Gastroenterol 1981; 16: 775-780 [PMID: 6459642 DOI: 10.3109/00365528109181003]
81. Gatta A, Merkel C, Grassetto M, Milani L, Zuin R, Ruol A. Enhanced renal sympathetic tone in liver cirrhosis: evaluation by intrarenal administration of dihydroergocristine. Nephron 1982; 30: 364-367 [PMID: 6810190 DOI: 10.1159/000182519]
82. Sacerdoti D, Bolognesi M, Merkel C, Angeli P, Gatta A. Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology 1993; 17: 219-224 [PMID: 8428719]
83. Almdal T, Schroeder T, Ranek L. Cerebral blood flow and liver function in patients with encephalopathy due to acute and chronic liver diseases. Scand J Gastroenterol 1989; 24: 299-303 [PMID: 2734587 DOI: 10.3109/00365528909093050]
84. Dillon JF, Plevris JN, Wong FC, Chan KH, Lo NT, Miller JD, Bouchier IA, Hayes PC. Middle cerebral artery blood flow velocity in patients with cirrhosis. Eur J Gastroenterol Hepatol 1995; 7: 1087-1091 [PMID: 8680909 DOI: 10.1097/0004737-199 511000-00012]
85. Guevara M, Bru C, Ginès P, Fernández-Esparrach G, Sort P, Bataller R, Jiménez W, Arroyo V. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 1998; 28: 39-44 [PMID: 9657094 DOI: 10.1002/hep.510280107]
86. Dam M, Burra P, Tedeschi U, Cagnin A, Chierichetti F, Ermani M, Ferlin G, Naccarato R, Pizzolato G. Regional cerebral blood flow changes in patients with cirrhosis assessed with 99mTc-HM-PAO single-photon emission computed tomography: effect of liver transplantation. J Hepatol 1998; 29: 78-84 [PMID: 9696495 DOI: 10.1016/S0168-8278(98)80181-5]
87. Maroto A, Ginès P, Arroyo V, Ginès A, Saló J, Clària J, Jiménez W, Bru C, Rivera F, Rodés J. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993; 17: 788-793 [PMID: 8491446]
88. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, Erlinger S, Lebrec D. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565-570 [PMID: 9824265]
89. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-1697 [PMID: 10347109 DOI: 10.1002/hep.510290629]
90. Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-48 [PMID: 10905585 DOI: 10.1016/S0168-8278(00)80158-0]
91. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-1318 [PMID: 17389705 DOI: 10.1136/gut.2006.107789]
92. Lieberman FL, Reynolds TB. Plasma volume in cirrhosis of the liver: its relation of portal hypertension, ascites, and renal failure. J Clin Invest 1967; 46: 1297-1308 [PMID: 16695918 DOI: 10.1172/JCI105622]
93. Zimmon DS, Kessler RE. The portal pressure-blood volume relationship in cirrhosis. Gut 1974; 15: 99-101 [PMID: 4820643 DOI: 10.1136/gut.15.2.99]
94. Bosch J, Arroyo V, Betriu A, Mas A, Carrilho F, Rivera F, Navarro-Lopez F, Rodes J. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980; 78: 92-99 [PMID: 7350041]
95. Angeli P, Caregaro L, Menon F, Sacerdoti D, De Toni R, Merkel C, Gatta A. Variability of atrial natriuretic peptide plasma levels in ascitic cirrhotics: pathophysiological and clinical implications. Hepatology 1992; 16: 1389-1394 [PMID: 1446894 DOI: 10.1002/hep.1840160614]
96. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-1157 [PMID: 2971015]
97. Okumura H, Aramaki T, Katsuta Y, Satomura K, Akaike M, Sekiyama T, Terada H, Ohsuga M, Komeichi H, Tsutsui H. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991; 86: 46-52 [PMID: 1986554]
98. García-Pagán JC, Salmerón JM, Feu F, Luca A, Ginés P, Pizcueta P, Claria J, Piera C, Arroyo V, Bosch J. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994; 19: 1095-1099 [PMID: 8175131 DOI: 10.1002/hep.1840190506]
99. Bernardi M, Di Marco C, Trevisani F, De Collibus C, Fornalé L, Baraldini M, Andreone P, Cursaro C, Zacá F, Ligabue A. The hemodynamic status of preascitic cirrhosis: an evaluation under steady-state conditions and after postural change. Hepatology 1992; 16: 341-346 [PMID: 1386333 DOI: 10.1002/ hep.1840160210]
100. Bernardi M, Trevisani F. Systemic and regional hemodynamics in pre-ascitic cirrhosis. J Hepatol 1997; 27: 588-591 [PMID: 9314140 DOI: 10.1016/S0168-8278(97)80367-4]
101. Møller S, Hobolth L, Winkler C, Bendtsen F, Christensen E. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 2011; 60: 1254-1259 [PMID: 21504996 DOI: 10.1136/gut.2010.235473]
102. Lee SS, Marty J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. Hepatology 1990; 12: 481-485 [PMID: 2169452 DOI: 10.1002/hep.1840120306]
103. Ma Z, Lee SS, Meddings JB. Effects of altered cardiac membrane fluidity on beta-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. J Hepatol 1997; 26: 904-912 [PMID: 9126806 DOI: 10.1016/S0168-8278(97)80259-0]
104. Lee RF, Glenn TK, Lee SS. Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21: 125-140 [PMID: 17223501 DOI: 10.1016/j.bpg.2006.06.003]
105. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762-768 [PMID: 20638742 DOI: 10.1016/j.jhep.2010.06.004]
106. Gatta A, Sacerdoti D, Merkel C, Milani L, Battaglia G, Zuin R. Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension. Am Heart J 1984; 108: 1167-1172 [PMID: 6148880 DOI: 10.1016/0002-8703(84)90602-1]
107. Morales J, Moitinho E, Abraldes JG, Fernández M, Bosch J. Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats. Hepatology 2003; 38: 1378-1383 [PMID: 14647048 DOI: 10.1016/ j.hep.2003.09.023]
108. Villanueva C, Ortiz J, Miñana J, Soriano G, Sàbat M, Boadas J, Balanzó J. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001; 121: 110-117 [PMID: 11438499 DOI: 10.1053/gast.2001.25536]
109. Moore CM, Van Thiel DH. Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J Hepatol 2013; 5: 251-263 [PMID: 23717736 DOI: 10.4254/wjh.v5.i5.251]
110. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417 [PMID: 20633946 DOI: 10.1016/j.jhep.2010.05.004]
111. Singh V, Kumar R, Nain CK, Singh B, Sharma AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol 2006; 21: 303-307 [PMID: 16460491 DOI: 10.1111/ j.1440-1746.2006.04182.x]
112. Singh V, Dheerendra PC, Singh B, Nain CK, Chawla D, Sharma N, Bhalla A, Mahi SK. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol 2008; 103: 1399-1405 [PMID: 18547224 DOI: 10.1111/ j.1572-0241.2008.01787.x]
113. Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, Bhalla A, Gupta PK. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol 2012; 56: 348-354 [PMID: 21749847 DOI: 10.1016/j.jhep.2011.04.027]
114. Narahara Y, Kanazawa H, Taki Y, Kimura Y, Atsukawa M, Katakura T, Kidokoro H, Harimoto H, Fukuda T, Matsushita Y, Nakatsuka K, Sakamoto C. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 2009; 24: 1791-1797 [PMID: 19686420 DOI: 10.1111/j.1440-1746.2009.05873.x]
115. Hasper D, Jörres A. New insights into the management of hepato-renal syndrome. Liver Int 2011; 31 Suppl 3: 27-30 [PMID: 21824281 DOI: 10.1111/j.1478-3231.2011.02586.x]